Lymphocyte Apoptosis and FAS Expression in Patients with 22q11.2 Deletion Syndrome
- 69 Downloads
Immunodeficiency is one of the key features of 22q11.2 deletion syndrome (del), and it is seen in approximately 75% of the patients. The degree of immunodeficiency varies widely, from no circulating T cells to normal T cell counts. It has been hypothesized that the low number of T cells may at least in part be due to increased apoptosis of T cells. Increased spontaneous T cell apoptosis has been reported in one patient with 22q11.2del, but this has not been further investigated.
A national cohort of patients with a proven heterozygous deletion of chromosome 22q11.2 diagnosed by FISH or MLPA and a group of age and sex matched controls were studied. Spontaneous and activation-induced apoptosis, in addition to FAS expression on lymphocytes, were measured using flow cytometry. Serum levels of FASL were analyzed using ELISA.
There was no increased spontaneous apoptosis in patients with 22q11.2del. Upon activation, anti-FAS-induced apoptosis was significantly increased in patients compared to those in controls, while there was no difference in activation induced cell death or activated cell autonomous death. We also found a significant increase in expression of FAS on freshly isolated lymphocytes from patients, while there was no difference in serum levels of FASL. Patients with congenital heart defects (CHD) had significantly higher serum levels of FASL compared to non-CHD patients.
We have shown increased FAS expression on lymphocytes from patients with 22q11.2del as well as increased levels of FASL in patients with CHD. Those changes may contribute to the pathophysiology of the 22q11.2del.
Keywords22q11.2del 22q11.2 deletion syndrome FAS FAS-L primary immunodeficiencie apoptosis
The authors would like to thank the patients, controls, and their families for participating in the study. We thank Leiv Sandvik for valuable statistical advice. A special gratitude goes to Marianne S. Wright for valuable advice, tireless enthusiasm, and support.
This study was financed by The South-Eastern Norway Regional Health Authority, Renée, and Bredo Grimsgaard’s Foundation, Henrik Homans Foundation, and Eckbos Foundation.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 5.Crowley B, Ruffner M, McDonald McGinn DM, Sullivan KE. Variable immune deficiency related to deletion size in chromosome 22q11.2 deletion syndrome. Am J Med Genet A. 2018. https://doi.org/10.1002/ajmg.a.38597.
- 15.de la Fuente MA, Recher M, Rider NL, Strauss KA, Morton DH, Adair M, et al. Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia. J Allergy Clin Immunol. 2011;128(1):139–46. https://doi.org/10.1016/j.jaci.2011.03.042.CrossRefGoogle Scholar
- 26.Choi K, Ni L, Jonakait GM. Fas ligation and tumor necrosis factor alpha activation of murine astrocytes promote heat shock factor-1 activation and heat shock protein expression leading to chemokine induction and cell survival. J Neurochem. 2011;116(3):438–48. https://doi.org/10.1111/j.1471-4159.2010.07124.x.CrossRefGoogle Scholar
- 33.Miyoshi T, Hosoda H, Nakai M, Nishimura K, Miyazato M, Kangawa K, et al. Maternal biomarkers for fetal heart failure in fetuses with congenital heart defects or arrhythmias. Am J Obstet Gynecol. 2018. https://doi.org/10.1016/j.ajog.2018.09.024.